Clinical trials: Thrombi
Coronary Artery Disease
DESTINY TRIAL (Inspiron x Biomatrix)
The main objective of this study is to evaluate the effectiveness of stent Inspiron ™ sirolimus-eluting and coating the abluminal biodegradable stent Biomatrix Flex ™ lesions in native coronary arteries.
- Trial name
- NCT01856088
- Testing
- Inspiron Stent, Biomatrix Flex Stent
- Where
- 10 sites in Brazil
- Volunteers
- 170 people
- Sponsor
- Scitech Produtos Medicos SA
Macular Edema, Retinal Vein Occlusion
Suprachoroidal Injection of Triamcinolone Acetonide With IVT Aflibercept in Subjects With Macular Edema Following RVO
This is a Phase 3, multicenter, randomized, masked, controlled, parallel group study of 12 months duration in treatment naïve subjects with RVO.
- Trial name
- SAPPHIRE (NCT02980874)
- Testing
- suprachoroidal CLS-TA, IVT aflibercept
- Where
- 110 sites in United States, Australia and 14 more
- Volunteers
- 460 people
- Sponsor
- Clearside Biomedical, Inc.
Atrial Fibrillation, Thromboembolism
AMPLATZER™ LAA Occluder Post Approval Study (PAS)
The aim of this multicenter, non-randomized observational post-approval is to compile real world outcome data on the use of an AMPLATZER LAA Occluder in subjects with non-valvular atrial fibrillation (NVAF).
- Conditions
- Atrial Fibrillation, Thromboembolism, Stroke
- Trial name
- NCT02964208
- Testing
- AMPLATZER™ LAA Occluder
- Where
- 22 sites in Argentina, Belgium and 5 more
- Volunteers
- 520 people
- Sponsor
- Abbott Medical Devices
Coagulation Defect; Bleeding
Quantra QPlus Sample Type Comparison
This is a single center prospective observational study to compare QPlus parameter measurements in arterial and venous blood samples collected in parallel from patients undergoing cardiac surgery.
- Trial name
- NCT05290675
- Testing
- Quantra QPlus System
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- HemoSonics LLC
End Stage Renal Disease, Thrombosis
Safety and Efficacy Study of AB023 (Xisomab 3G3) in End Stage Renal Disease Patients on Chronic Hemodialysis
This study evaluates the safety and efficacy of AB023 (xisomab 3G3) in patients with end stage renal disease on chronic hemodialysis. Two dose levels will be evaluated in two cohorts.
- Trial name
- NCT03612856
- Testing
- AB023- Dose 1, AB023-Dose 2
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Aronora, Inc.
Thrombosis
Bioavailability Study Comparing Modified Release To Immediate Release Apixaban Tablets In Healthy Volunteers
To estimate the pharmacokinetics of apixaban when administered as three different modified release formulation tablets relative to that when apixaban is administered as an immediate release tablet
- Trial name
- NCT00914641
- Testing
- Apixaban IR, Apixaban MR1, Apixaban MR2
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Pfizer
Pulmonary Embolism
SaExten Vena Cava Filter System in Prevention of Pulmonary Embolism
The purpose of this study is to evaluate the efficacy and safety of SaExten vena cava filter (VCF) system (ShenZhen KYD BioTech Co., Ltd., China) in prevention of pulmonary embolism (PE).
- Trial name
- NCT04948502
- Testing
- SaExten vena cava filter system, Denali inferior vena cava filter
- Where
- 16 sites in China
- Volunteers
- 192 people
- Sponsor
- ShenZhen KYD Biomedical Technology Co., Ltd.
Coronary Artery Disease
ABSORB II Randomized Controlled Trial
Prospective, randomized (2:1), active control, single blinded, parallel two-arm, multi-center clinical investigation using Abbott Vascular ABSORB Everolimus Eluting Bioresorbable Vascular Scaffold System (ABSORB BVS); compared to…
- Trial name
- ABSORB II (NCT01425281)
- Testing
- Abbott Vascular XIENCE Everolimus Eluting Coronary Stent System, Abbott Vascular ABSORB Everolimus Eluting Bioresorbable Vascular Scaffold System
- Where
- Belgium
- Volunteers
- 501 people
- Sponsor
- Abbott Medical Devices
Stroke, Acute, Stroke, Ischemic
Magnetically Enhanced Diffusion for Acute Ischaemic Stroke (MEDIS) Trial
The objective of the MEDIS study is to determine if subjects experiencing an Acute Ischaemic Stroke due to large vessel occlusion, treated with IV tPA combined with the MED procedure have a greater likelihood of recanalisation…
- Conditions
- Stroke, Acute, Stroke, Ischemic, Infarction, Middle Cerebral Artery, Strokes Thrombotic
- Trial name
- MEDIS (NCT03098732)
- Testing
- Magnetically Enhanced Diffusion (MED)
- Where
- 2 sites in United Kingdom
- Volunteers
- 120 people
- Sponsor
- Pulse Therapeutics
Cerebral Embolicprotection Device, TAVR
Cerebral Embolic Protection Device During TAVR
To evaluate the safety and effectiveness of the Cerebral Protection System (model CEP016F, Shanghai Shenqi Medical Technology Co., Ltd.) for capturing and removing thrombotic and tissue debris during transcatheter aortic valve…
- Trial name
- NCT07627984
- Testing
- Cerebral embolic protection device
- Where
- China
- Volunteers
- 260 people
- Sponsor
- Shanghai Shenqi Medical Technology Co., Ltd
Blood Loss, Thrombosis
Exploratory Assessment of the Quantra® System in Adult ECMO Patients
This is a prospective, observational exploratory study of the performance of the Quantra System in adult patients that are undergoing an arterio-venous (AV), veno-venous (VV) ECMO or extra-corporeal life support (ECLS) procedure.
- Conditions
- Blood Loss, Thrombosis, Extracorporeal Circulation; Complications
- Trial name
- NCT05426564
- Testing
- Quantra System
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- HemoSonics LLC
Coronary Disease, Coronary Artery Disease
Safety and Efficacy of the ZoMaxx™ Drug-Eluting Stent System in Coronary Arteries
The purpose of this study is to demonstrate the safety and efficacy of the ZoMaxx drug-eluting stent in patients with blockage of native coronary arteries.
- Conditions
- Coronary Disease, Coronary Artery Disease, Coronary Restenosis
- Trial name
- ZoMaxx™ I (NCT00148356)
- Testing
- ZoMaxx™ Drug-Eluting Coronary Stent System, TAXUS™ EXPRESS2™ Paclitaxel Eluting Coronary Stent System
- Where
- 29 sites in Australia, Belgium and 8 more
- Volunteers
- 401 people
- Sponsor
- Abbott Medical Devices
Healthy
Evaluation of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effects of PER977 Following Heparin
Normal subjects will receive unfractionated heparin followed by a single dose of PER977 with dose escalation by cohort. Ten subjects enrolled in Cohort 4 will receive a single dose of PER977 followed by a one-week washout and…
- Trial name
- NCT02206087
- Testing
- PER977, Heparin Sodium
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, Inc.
Arteriovenous Graft Thrombosis
AVATR - Arteriovenous Access Thrombosis Removal With CAPERE Thrombectomy System
A prospective, single-arm, non-blinded study, intending to treat and collect and evaluate data in up to ten (10) human subjects who are currently being treated with hemodialysis and who present with acute thrombosis in their…
- Trial name
- AVATR (NCT04494035)
- Testing
- CAPERE Thrombectomy System
- Where
- Canada
- Volunteers
- 7 people
- Sponsor
- Medtronic Endovascular
Congenital Bleeding Disorder, Congenital FXIII Deficiency
Comparison of a Blood Clotting Drug (Recombinant Factor XIII) Produced by Two Different Manufacturers in Healthy Male Subjects
This trial is conducted in Europe. The aim of this clinical trial is to compare the metabolism of a blood-clotting drug (recombinant Factor XIII)) produced by two different manufacturers (Novo Nordisk and Avecia) in healthy male…
- Conditions
- Congenital Bleeding Disorder, Congenital FXIII Deficiency, Healthy
- Trial name
- NCT01082406
- Testing
- catridecacog, recombinant factor XIII
- Where
- United Kingdom
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Stable Angina
COBRA SHIELD OCT Study
Phase one of this study is a prospective, randomized (2:1), pilot study that will evaluate COBRA PzF vascular healing patterns and thrombus formation with Optical Coherence Tomography (OCT) at 3 months after stent implantation in…
- Trial name
- NCT02224235
- Testing
- Aspirin, Resolute Integrity DES, COBRA PzF
- Where
- 2 sites in Finland
- Volunteers
- 8 people
- Sponsor
- CeloNova BioSciences, Inc.
Raynaud's Disease, Raynaud's Disease Secondary to Scleroderma
A Study of a Topical Form of Nitroglycerin and Placebo in the Treatment and Prevention of Raynaud's Phenomenon
The purpose of this research study is to test the safety, tolerability, and effectiveness of Topical AmphiMatrix with Nitroglycerin (MQX0503) to relieve Raynaud's symptoms and increase blood flow to the fingers.
- Conditions
- Raynaud's Disease, Raynaud's Disease Secondary to Scleroderma, Raynaud's Disease Secondary to Other Autoimmune Disease
- Trial name
- NCT00577304
- Testing
- Nitroglycerin, Topical AmphiMatrix
- Where
- 17 sites in United States
- Volunteers
- 200 people
- Sponsor
- MediQuest Therapeutics
Coronary Artery Disease, Cerebro Vascular Disease
Study the Result of Ayurvedic SUVED & Reimmugen (Colostrum) Treatment on Vascular Disease, CAD, CVA, DVT.
To evaluate the benefits of Ayurvedic SUVED \& REIMMUGEN Colostrum for reduction/reversal of symptoms and study clinical progress in Vascular disease; CAD, CAV, Stroke, DVT patients.
- Conditions
- Coronary Artery Disease, Cerebro Vascular Disease, Ischemic Heart Disease, Deep Vein Thrombosis
- Trial name
- SHARP (NCT02920125)
- Testing
- SUVED, REIMMUGEN
- Where
- India
- Volunteers
- 96 people
- Sponsor
- Sujata Vaidya
Treatment of Venous Thromboembolism in Cancer Patients
A Study to Gather Information About Rivaroxaban in Patients in Sweden With Cancer Who Also Have Thrombosis (OSCAR-SE)
This is an observational study in which patient data from the past on venous thromboembolism (VTE) in patients with cancer is studied.
- Trial name
- NCT05150938
- Testing
- Rivaroxaban (Xarelto, BAY59-7939), Low molecular weight heparin (LMWH), vitamin K antagonist (VKA)
- Where
- Sweden
- Volunteers
- 5,737 people
- Sponsor
- Bayer
Thrombosis
Etude (Study) Phase I Enox - UnFractionated Heparin (UFH)
Primary objective: to characterize the pharmacokinetic and the pharmacodynamic profile after intravenous bolus injection of unfractionated heparin (UFH) after repeated sc 100 IU anti-Xa/kg (corresponding to 1 mg/kg) twice a day…
- Trial name
- NCT00622115
- Testing
- Enoxaparin
- Where
- France
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Sanofi